Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Description

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Conditions

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Condition
Relapsed Adult AML
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama - Birmingham, Birmingham, Alabama, United States, 35294

Stanford

Stanford University, Stanford, California, United States, 94305

Denver

University of Colorado Denver I Anschutz Medical Campus, Denver, Colorado, United States, 80204

Miami

University of Miami, Miami, Florida, United States, 33146

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Evanston

Northwestern University, Evanston, Illinois, United States, 60208

Bloomington

Indiana University, Bloomington, Indiana, United States, 47405

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21218

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient Inclusion Criteria
  • * Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
  • * Patients with new diagnosis ≥ 60 years of age
  • * An antecedent hematologic disorder
  • * Therapy related-disease
  • * Relapsed or primary refractory AML
  • * Receiving treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial
  • * Caregiver Inclusion Criteria
  • * Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.
  • * Patient Exclusion Criteria
  • * Patients with a diagnosis of acute promyelocytic leukemia (APML)
  • * Patients with AML receiving supportive care alone
  • * Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
  • * Patients seen by a palliative care clinician \[MD or APP\] during two previous hospitalizations in the six months prior to enrollment

Ages Eligible for Study

18 Years to 120 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Massachusetts General Hospital,

Areej El-Jawahri, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Jennifer Temel, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2029-04